Cancer Therapy Advisor

CancerTherapyAdvisor.com is a no-cost online platform designed for oncology healthcare providers. It provides a thorough collection of practical information and clinical tools related to cancer care, helping professionals make informed decisions for their patients.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#401361

United States

#164217

Health/Health Conditions and Concerns

#401

Traffic sources

Monthly visitors

Articles

Adjuvant Cemiplimab Could Be New Standard of Care for High-Risk CSCC

6 days ago | cancertherapyadvisor.com | Erin Clancy

Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous squamous cell carcinoma (CSCC) who have completed adjuvant radiotherapy and have a high risk of recurrence, according to research presented at the ASCO Annual Meeting 2025.1 “[C]emiplimab is the only systemic therapy to demonstrate a statistically significant and clinically meaningful reduction in disease recurrence as adjuvant therapy for patients at high risk of CSCC recurrence,” said study presenter...
Switching Therapy After Detection of ESR1 Mutations Improves PFS in ER+/HER2- Breast Cancer

1 week ago | cancertherapyadvisor.com | Vicki Moore

Switching first-line therapy upon detection of ESR1 mutations can be beneficial for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, results from the phase 3 SERENA-6 trial suggest.1,2 The trial showed that patients who were receiving first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor had an improvement in progression-free survival (PFS) if they switched to treatment with camizestrant and a CDK4/6 inhibitor upon detection of ESR1...
AI Can Reduce Misclassification of HER2-Low and HER2-Ultralow Breast Cancers

1 week ago | cancertherapyadvisor.com | Julie Ehlers

An online training platform integrated with artificial intelligence (AI) can help pathologists identify HER2-low and HER2-ultralow breast cancers with more accuracy, according to research presented at the ASCO Annual Meeting 2025. Use of AI assistance reduced the misclassification of HER2-low and HER2-ultralow breast cancers as HER2-null by 24%, said study presenter Marina De Brot, MD, PhD, of A.C. Camargo Cancer Center in São Paulo, Brazil.
Adding Perioperative Systemic Therapy to CRS-HIPEC Improves PFS, Not OS

1 week ago | cancertherapyadvisor.com | Jen Smith

Adding perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can improve some outcomes in patients with resectable colorectal peritoneal metastases, according to research presented at the ASCO Annual Meeting 2025. This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).
First Generic Version of Tasigna Now Available

1 week ago | cancertherapyadvisor.com | Diana Ernst

Apotex has launched the first generic version of Tasigna (nilotinib capsules), a tyrosine kinase inhibitor (TKI) approved to treat patients with chronic myeloid leukemia (CML).
Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

1 week ago | cancertherapyadvisor.com | Victoria Forster

First-line treatment with alectinib and bevacizumab appears to be effective for patients with ALK-rearranged, metastatic non-small cell lung cancer (NSCLC), according to researchers. They reported results with the combination in Nature Communications. The researchers evaluated alectinib and bevacizumab in the phase 2 ALEK-B trial (NCT03779191), which included 41 patients with treatment-naïve, metastatic, ALK-rearranged NSCLC.
Science Under Siege: What Can You Do to Advocate for Cancer Research?

1 week ago | cancertherapyadvisor.com | Erin Clancy

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research as the Trump administration continues to reduce federal research funding.1-3 The administration has now terminated more than 1000 grants issued by the National Institutes of Health (NIH), some in defiance of court orders.4-7 The NIH has also frozen grants to universities and withheld funding from grant recipients who participate in diversity, equity, and inclusion/accessibility...
Rising Cancer Cases in Young Women Prompt Call to Action

1 week ago | cancertherapyadvisor.com | Julie Ehlers

City of Hope and the American Cancer Society (ACS) are calling for changes to combat the rising cancer rates observed among young women in the United States.1,3 According to ACS data, the cancer incidence in women increased 23% during 1978-2021, and cancer rates among women younger than 50 years of age were 82% higher than cancer rates among men in the same age group in 2021.1,2 “For more than 20 years, we’ve been seeing a concerning and steady trend, which is rising cancer rates among...
FDA’s New Approach to Evaluating COVID-19 Vaccines Will Limit Access, Officials Say

1 week ago | cancertherapyadvisor.com | Erin Clancy

The US Food and Drug Administration (FDA) is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines and ultimately limit who can be vaccinated, according to a viewpoint by FDA officials that was published in The New England Journal of Medicine.1 The FDA will continue to evaluate individual applications for COVID-19 vaccines on a case-by-case basis, but the agency will adopt different standards for approval according to the patient populations...
Cuts to Medicare Reimbursement May Force Practices to Close

2 weeks ago | cancertherapyadvisor.com | Jen Smith

Cuts to Medicare reimbursement for radiation therapy could prevent cancer patients from accessing care and force practices to downsize or close, according to a survey conducted by the American Society for Radiation Oncology (ASTRO).1 ASTRO surveyed 675 US-based, non-emeritus radiation oncologists about the potential impacts of cuts to Medicare reimbursement, and 96% of respondents said cuts would impede patients’ access to care.